Daiana Stolz1, Mirjam Christ-Crain2, Nils G Morgenthaler3, David Miedinger4, Jörg Leuppi4, Christian Müller5, Roland Bingisser5, Joachim Struck3, Beat Müller2, Michael Tamm4. 1. Clinic of Pneumology and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland. Electronic address: stolzd@uhbs.ch. 2. Clinic of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Basel, Basel, Switzerland. 3. Research Department, BRAHMS AG, Biotechnology Centre, Hennigsdorf, Germany. 4. Clinic of Pneumology and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland. 5. Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND: Plasma endothelin and adrenomedullin are increased in patients with pulmonary arterial hypertension, hypoxia, and pulmonary infections, conditions that predict survival in patients with COPD. We investigated whether plasma pro-endothelin-1 (proET-1) and/or pro-adrenomedullin (proADM) on admission to the hospital for acute exacerbation predict survival in patients with COPD. METHODS: We examined 167 patients who had been admitted to the hospital for acute exacerbation, and we followed them up for 2 years. We measured plasma C-terminal (CT) proET-1 and mid-regional (MR) proADM on hospital admission, after 14 to 18 days, and after 6 months. In addition to plasma CT proET-1 and MR proADM, we assessed with Cox regression univariate and multivariate analyses the predictive value of clinical, functional, and laboratory parameters on 2-year survival. We analyzed the time to death by Kaplan-Meier curves. RESULTS: Compared to recovery and stable state, CT-proET-1 and MR-proADM were significantly increased on hospital admission (p < 0.001 and p = 0.002, respectively). MR-proADM, but not CT-proET-1, was associated with increased in-hospital mortality (p = 0.049) and independently predicted 2-year survival (p = 0.017). ProADM plasma levels > 0.84 nmol/L on hospital admission increased the mortality risk within 2 years from 13 to 32% (p = 0.004). By contrast, age (p = 0.779), Charlson comorbidity score (p = 0.971), body mass index (p = 0.802), FEV(1) percent predicted (p = 0.741), PAo(2) (p = 0.744), PAco(2) (p = 0.284), leukocyte counts (p = 0.333), C-reactive protein (p = 0.772), procalcitonin (p = 0.069), pulmonary arterial hypertension (p = 0.971), and CT-proET-1 (p = 0.223) were not independently associated with 2-year survival. CONCLUSIONS: This study shows that plasma proADM but not plasma proET-1 on admission to the hospital for acute exacerbation independently predicts survival, thus suggesting that this biomarker could be used to predict prognosis in patients with COPD.
BACKGROUND: Plasma endothelin and adrenomedullin are increased in patients with pulmonary arterial hypertension, hypoxia, and pulmonary infections, conditions that predict survival in patients with COPD. We investigated whether plasma pro-endothelin-1 (proET-1) and/or pro-adrenomedullin (proADM) on admission to the hospital for acute exacerbation predict survival in patients with COPD. METHODS: We examined 167 patients who had been admitted to the hospital for acute exacerbation, and we followed them up for 2 years. We measured plasma C-terminal (CT) proET-1 and mid-regional (MR) proADM on hospital admission, after 14 to 18 days, and after 6 months. In addition to plasma CT proET-1 and MR proADM, we assessed with Cox regression univariate and multivariate analyses the predictive value of clinical, functional, and laboratory parameters on 2-year survival. We analyzed the time to death by Kaplan-Meier curves. RESULTS: Compared to recovery and stable state, CT-proET-1 and MR-proADM were significantly increased on hospital admission (p < 0.001 and p = 0.002, respectively). MR-proADM, but not CT-proET-1, was associated with increased in-hospital mortality (p = 0.049) and independently predicted 2-year survival (p = 0.017). ProADM plasma levels > 0.84 nmol/L on hospital admission increased the mortality risk within 2 years from 13 to 32% (p = 0.004). By contrast, age (p = 0.779), Charlson comorbidity score (p = 0.971), body mass index (p = 0.802), FEV(1) percent predicted (p = 0.741), PAo(2) (p = 0.744), PAco(2) (p = 0.284), leukocyte counts (p = 0.333), C-reactive protein (p = 0.772), procalcitonin (p = 0.069), pulmonary arterial hypertension (p = 0.971), and CT-proET-1 (p = 0.223) were not independently associated with 2-year survival. CONCLUSIONS: This study shows that plasma proADM but not plasma proET-1 on admission to the hospital for acute exacerbation independently predicts survival, thus suggesting that this biomarker could be used to predict prognosis in patients with COPD.
Authors: Francisco Valenzuela-Sánchez; Blanca Valenzuela-Méndez; Juan Francisco Rodríguez-Gutiérrez; Ángel Estella-García; María Ángela González-García Journal: Ann Transl Med Date: 2016-09
Authors: David T Huang; Derek C Angus; John A Kellum; Nathan A Pugh; Lisa A Weissfeld; Joachim Struck; Russell L Delude; Matthew R Rosengart; Donald M Yealy Journal: Chest Date: 2009-04-10 Impact factor: 9.410
Authors: B Suberviola; A Castellanos-Ortega; A Ruiz Ruiz; M Lopez-Hoyos; M Santibañez Journal: Intensive Care Med Date: 2013-08-16 Impact factor: 17.440
Authors: Alicia Lacoma; Cristina Prat; Felipe Andreo; Luis Lores; Juan Ruiz-Manzano; Vicente Ausina; Jose Domínguez Journal: Int J Chron Obstruct Pulmon Dis Date: 2011-02-28
Authors: Mihael Potocki; Tobias Breidthardt; Tobias Reichlin; Nils G Morgenthaler; Andreas Bergmann; Markus Noveanu; Nora Schaub; Heiko Uthoff; Heike Freidank; Lorenz Buser; Roland Bingisser; Michael Christ; Alexandre Mebazaa; Christian Mueller Journal: Crit Care Date: 2009-07-23 Impact factor: 9.097
Authors: Daniel Drozdov; Anja Thomer; Marc Meili; Stefanie Schwarz; Rita Bossart Kouegbe; Katharina Regez; Merih Guglielmetti; Ursula Schild; Antoinette Conca; Petra Schäfer; Barbara Reutlinger; Cornelia Ottiger; Florian Buchkremer; Alexander Litke; Philipp Schuetz; Andreas Huber; Ulrich Bürgi; Christoph A Fux; Andreas Bock; Beat Müller; Werner C Albrich Journal: Trials Date: 2013-03-22 Impact factor: 2.279
Authors: Victor Pinto-Plata; Ciro Casanova; Hana Müllerova; Juan P de Torres; Henneth Corado; Nerea Varo; Elizabeth Cordoba; Salah Zeineldine; Hildegarde Paz; Rebeca Baz; Miguel Divo; Felipe Cortopassi; Bartolome R Celli Journal: Respir Res Date: 2012-08-20